The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillofacial trauma

In recent years, recombinant human bone morphogenetic protein-2 (rhBMP-2) has been introduced as a therapeutic option in the treatment of several congenital and acquired craniofacial defects. Although there have been promising clinical results, the international literature still lacks complete guide...

Descripción completa

Detalles Bibliográficos
Autor principal: Herford, A.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343095/
https://www.ncbi.nlm.nih.gov/pubmed/28236566
http://dx.doi.org/10.1016/j.cjtee.2016.05.004
Descripción
Sumario:In recent years, recombinant human bone morphogenetic protein-2 (rhBMP-2) has been introduced as a therapeutic option in the treatment of several congenital and acquired craniofacial defects. Although there have been promising clinical results, the international literature still lacks complete guidelines, including limits and indications for the use of rhBMP-2. The possible indications for rhBMP-2 in patients undergoing facial trauma are discussed in this article.

Ejemplares similares